Search

Current Clinical Trials

 

Adult Trials

Crohn's Disease

  • Protocol: GS-US-419-3895

    Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease.

    Learn More
  • Protocol: GS-US-419-3896

    A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease.

    Learn More
  • Protocol: RPC01-3202

    Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.

    Learn More
  • Protocol: RPC01-3203

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease.

    Learn More
  • Protocol: RPC01-3204

    A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease.

    Learn More
  • Protocol: RPC01-0173

    A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn’s Disease.

    Learn More
  • Protocol: 64304500CRD2001

    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease.

    Learn More
  • Protocol: CNTO1275CRD3007

    A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderately-to-Severely Active Crohn’s Disease.

    Learn More
  • Protocol: CNTO1959CRD3001

    A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease.

    Learn More

Diabetic Gastroparesis

  • Protocol: RLM-MD-01

    A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

    Learn More
  • Protocol: RLM-MD-03

    A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

    Learn More
  • Protocol: RLM-MD-04

    A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

    Learn More

Eosinophilic Esophagitis

  • Protocol: R668-EE-1774

    A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE).

    Learn More

Irritable Bowel Syndrome in Women

  • Protocol: URO-901-2001

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women with Irritable Bowel Syndrome.

    Learn More

Non-alcoholic Steatohepatitis (NASH)

  • Protocol: 3152-301-002

    EAURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis.

    Learn More
  • Protocol: EDP-305-101

    A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohepatitis (NASH).

    Learn More
  • Protocol: GFT505-315-1

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

    Learn More

Perianal Fistulizing Crohn's Disease

  • Protocol: GS-US-419-4016

    A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease.

    Learn More

Small Bowel Crohn's Disease

  • Protocol: GS-US-419-4015

    A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD).

    Learn More

Testicular Safety for Ulcerative Colitis

  • Protocol: GS-US-418-4279

    A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis.

    Learn More

Ulcerative Colitis

  • Protocol: M14-234

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.

    Learn More
  • Protocol: M14-533

    A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis.

    Learn More
  • Protocol: M14-675

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis.

    Learn More
  • Protocol: GS-US-418-3898

    Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.

    Learn More
  • Protocol: GS-US-418-3899

    A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis.

    Learn More
  • Protocol: SERES-201

    ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults with Active Mild-to-Moderate Ulcerative Colitis.

    Learn More
  • Protocol: Vedolizumab-4014

    A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET).

    Learn More
  • Protocol: I6T-MC-AMAN

    A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis. LUCENT 1

    Learn More
  • Protocol: I6T-MC-AMBG

    A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis. LUCENT 2

    Learn More

Pediatric Trials

Eosinophilic Esophagitis

  • Protocol: R668-EE-1774

    A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE).

    Learn More

Ulcerative Colitis

  • Protocol: CNTO148UCO3003

    A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis.

    Learn More

Be in the know. Get the latest updates on digestive health.

Copyright 2019 by DHAT - Digestive Health Association of Texas. Terms Of Use |  Privacy Statement
Back To Top